184 filings
Page 3 of 10
CORRESP
lfd8qsu0nh5hj
1 Jun 23
Correspondence with SEC
12:00am
6-K
pt6l4 8d6y
18 May 23
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
6:05am
CORRESP
ta82yiht
12 May 23
Correspondence with SEC
12:00am
F-1/A
ipy2j9e8
11 May 23
Registration statement (foreign) (amended)
4:01pm
6-K
ssqmh
11 May 23
Current report (foreign)
6:00am
CORRESP
d77w66u ftf
11 May 23
Correspondence with SEC
12:00am
6-K
tb233ptxjhohtk0bqz
10 May 23
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
6:05am
UPLOAD
jlym fxljbwca
9 May 23
Letter from SEC
12:00am
6-K
37exedry
5 May 23
Addex Convenes Annual General Meeting 2023
6:05am
F-1
b8hwbd5910v1mr 8t
3 May 23
Registration statement (foreign)
4:06pm
D
d6v6lc
13 Apr 23
$3.73 mm in equity / options / securities to be acquired, sold $3.73 mm, 1 investor
8:14am
424B5
7b0lgo d5u
4 Apr 23
Prospectus supplement for primary offering
5:19pm
6-K
fanokaog lysg6
4 Apr 23
Current report (foreign)
4:25pm
6-K
shc3cvbjs8emgyc3blx
4 Apr 23
Current report (foreign)
6:05am
6-K
pty3c5
3 Apr 23
Current report (foreign)
6:05am
6-K
977t6q10me biel
30 Mar 23
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
6:05am
6-K
ycnz0 yn9lveney
9 Feb 23
Current report (foreign)
6:05am
6-K
ni4wor h9o4zj3
6 Feb 23
Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
6:05am
6-K
wi8mr4ixqawyyg
19 Jan 23
Addex Provides Corporate Update and Financial Guidance
6:05am